(Reuters) -Madrigal Pharmaceuticals said on Wednesday it has entered into an up to $2 billion global license agreement with CSPC Pharmaceutical to develop an oral GLP-1 drug for a type of liver disease.
The U.S. drugmaker said it plans to start development of the experimental drug, SYH2086, for a fatty liver disease known as metabolic dysfunction-associated steatohepatitis (MASH) in the first half of 2026.
Madrigal’s Rezdiffra became the first drug to receive the U.S. Food and Drug Administration’s nod for the treatment of MASH in 2024.
Under the agreement, CSPC will receive an upfront payment of $120 million and is eligible to receive up to $2 billion in milestone payments if certain development, regulatory and commercial milestones are achieved, as well as royalties on net sales.
“We believe a combination of Rezdiffra and SYH2086 has the potential to deliver a best-in-class oral treatment for patients with MASH,” said Madrigal CEO Bill Sibold.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)
Comments